Articles On Amplia Therapeutics (ASX:ATX)

The Amplia Therapeutics Ltd (ASX: ATX) share price is up 16.67% since Tuesday’s open to 14 cents per share, as former Macquarie Group Ltd (ASX: MQG) CEO Allan Moss announced that he had become a substantial holder. What was in the announce...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has successfully completed the Institutional Entitlement Offer component of its fully underwritten, accelerated,...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has received preliminary final results from the preclinical toxicology studies being conducted with its FAK inhib...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has released a new investor presentation which provides an update on the Company’s technology and its near-term a...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

A quick wrap of the key winners and losers on Wednesday, May 20. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potential market-moving announcements during the day. WINNERS: CODE COMPANY PRICE...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received a second orphan drug designation from the US Food and Drug Administration for its focal adhesion kinase inhibitor AMP945. The designation has been awarded for the use of AMP...

A quick wrap of the key winners and losers on Tuesday, May 19. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potential market-moving announcements during the day.   WINNERS: Code Company Price...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has announced that the United States Food and Drug Administration (FDA) has awarded a second Orphan Drug Designat...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received regulatory approval from the US Food and Drug Administration (FDA) for its Focal Adhesion Kinase inhibitor (FAKi) AMP945 – a novel new treatment for pancreatic cancer. The c...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) today announced that the United States Food and Drug Administration (FDA) has awarded Amplia’s Focal Adhesion Kin...

What's happened? Amplia Therapeutics Limited (ATX:ASX, "Amplia") have made a key addition to their Scientific Advisory Board. What are the key highlights? Professor Paul Timpson has been appointed to Amplia's Scientific Advisory Board. Prof...

Our summary of Amplia Therapeutics Ltd's recent announcement What's happened? Amplia Therapeutics Limtied (ASX:ATX) have undertaken a capital raising. What are the key highlights? $0.93 million raised. Platinum International Healthcare Fun...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...

Headlines are being made in the US today with a Republican Congressman expected to plead guilty to insider trading charges brought by the US securities regulator the SEC. Making the case unusual is that the micro-cap biotech in question is...

Whatever you think of Audio Pixels (ASX:AKP) you cannot deny it’s been a spectacular investment for those who got in early. From 15c 10 years ago to $18.45 on Friday, it has gained over 12,000 per cent. It is the second greatest 10-year gai...

In the three months since Stockhead last looked at the performance of equity capital market firms – the market has seen several more deals and a couple of acquisitions. In June, Shaw and Partners revealed it was acquiring DJ Carmichael and...

Coming after trial flops from Factor Therapeutics (ASX:FTT), Innate Immunotherapeutics (now Amplia Therapeutics, ASX:ATX) and Bionomics (ASX:BNO), investors were awaiting the phase IIb results from the eye diseases house with more than a de...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

In this article, we would discuss three healthcare stocks from ASX. On 23 July 2019, these companies have released significant updates pertaining to their respective business. The Australian benchmark index was trading at 6,780.6, up by 55....

Amplia Therapeutics (ASX: AMP) shares surged this morning after announcing positive pre-clinical data for its anti-cancer drug. The drug, AMP945, targets Focal Adhesion Kinase (FAK). It’s a protein in humans that help cancer cells spread. (...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...